5323052026-07-012026-09-305323052026-09-305323052026-03-315323052026-04-012026-09-305323052026-07-012026-09-30in-capmkt:OtherExpenses1Member5323052026-04-012026-09-30in-capmkt:OtherExpenses1Member5323052026-09-30OtherNoncurrentFinancialAssetsDomain15323052026-09-30OtherNoncurrentAssetsDomain15323052026-09-30OtherCurrentFinancialAssetsDomain15323052026-09-30OtherCurrentAssetsDomain15323052026-09-30OtherNoncurrentFinancialLiabilitiesDomain15323052026-09-30OtherNoncurrentLiabilitiesDomain15323052026-09-30OtherCurrentFinancialLiabilitiesDomain15323052026-09-30OtherCurrentLiabilitiesDomain15323052026-07-012026-09-30RelatedPartyTransactionDomain15323052026-06-30RelatedPartyTransactionDomain15323052026-09-30RelatedPartyTransactionDomain15323052026-07-012026-09-30RelatedPartyTransactionDomain25323052026-06-30RelatedPartyTransactionDomain25323052026-09-30RelatedPartyTransactionDomain25323052026-07-012026-09-30RelatedPartyTransactionDomain35323052026-06-30RelatedPartyTransactionDomain35323052026-09-30RelatedPartyTransactionDomain35323052026-07-012026-09-30RelatedPartyTransactionDomain45323052026-06-30RelatedPartyTransactionDomain45323052026-09-30RelatedPartyTransactionDomain45323052026-07-012026-09-30RelatedPartyTransactionDomain55323052026-06-30RelatedPartyTransactionDomain55323052026-09-30RelatedPartyTransactionDomain55323052026-07-012026-09-30RelatedPartyTransactionDomain65323052026-06-30RelatedPartyTransactionDomain65323052026-09-30RelatedPartyTransactionDomain65323052026-07-012026-09-30RelatedPartyTransactionDomain75323052026-06-30RelatedPartyTransactionDomain75323052026-09-30RelatedPartyTransactionDomain75323052026-07-012026-09-30RelatedPartyTransactionDomain85323052026-06-30RelatedPartyTransactionDomain85323052026-09-30RelatedPartyTransactionDomain85323052026-07-012026-09-30RelatedPartyTransactionDomain95323052026-06-30RelatedPartyTransactionDomain95323052026-09-30RelatedPartyTransactionDomain95323052026-07-012026-09-30RelatedPartyTransactionDomain105323052026-06-30RelatedPartyTransactionDomain105323052026-09-30RelatedPartyTransactionDomain105323052026-07-012026-09-30RelatedPartyTransactionDomain115323052026-06-30RelatedPartyTransactionDomain115323052026-09-30RelatedPartyTransactionDomain115323052026-07-012026-09-30RelatedPartyTransactionDomain125323052026-06-30RelatedPartyTransactionDomain125323052026-09-30RelatedPartyTransactionDomain125323052026-07-012026-09-30RelatedPartyTransactionDomain135323052026-06-30RelatedPartyTransactionDomain135323052026-09-30RelatedPartyTransactionDomain135323052026-07-012026-09-30RelatedPartyTransactionDomain145323052026-06-30RelatedPartyTransactionDomain145323052026-09-30RelatedPartyTransactionDomain145323052026-07-012026-09-30RelatedPartyTransactionDomain155323052026-06-30RelatedPartyTransactionDomain155323052026-09-30RelatedPartyTransactionDomain155323052026-07-012026-09-30RelatedPartyTransactionDomain165323052026-06-30RelatedPartyTransactionDomain165323052026-09-30RelatedPartyTransactionDomain165323052026-07-012026-09-30RelatedPartyTransactionDomain175323052026-06-30RelatedPartyTransactionDomain175323052026-09-30RelatedPartyTransactionDomain175323052026-07-012026-09-30RelatedPartyTransactionDomain185323052026-06-30RelatedPartyTransactionDomain185323052026-09-30RelatedPartyTransactionDomain185323052026-07-012026-09-30RelatedPartyTransactionDomain195323052026-06-30RelatedPartyTransactionDomain195323052026-09-30RelatedPartyTransactionDomain195323052026-07-012026-09-30RelatedPartyTransactionDomain205323052026-06-30RelatedPartyTransactionDomain205323052026-09-30RelatedPartyTransactionDomain205323052026-07-012026-09-30RelatedPartyTransactionDomain215323052026-06-30RelatedPartyTransactionDomain215323052026-09-30RelatedPartyTransactionDomain215323052026-07-012026-09-30RelatedPartyTransactionDomain225323052026-06-30RelatedPartyTransactionDomain225323052026-09-30RelatedPartyTransactionDomain225323052026-07-012026-09-30RelatedPartyTransactionDomain235323052026-06-30RelatedPartyTransactionDomain235323052026-09-30RelatedPartyTransactionDomain235323052026-07-012026-09-30RelatedPartyTransactionDomain245323052026-06-30RelatedPartyTransactionDomain245323052026-09-30RelatedPartyTransactionDomain245323052026-07-012026-09-30RelatedPartyTransactionDomain255323052026-06-30RelatedPartyTransactionDomain255323052026-09-30RelatedPartyTransactionDomain255323052026-07-012026-09-30RelatedPartyTransactionDomain265323052026-06-30RelatedPartyTransactionDomain265323052026-09-30RelatedPartyTransactionDomain265323052026-07-012026-09-30RelatedPartyTransactionDomain275323052026-06-30RelatedPartyTransactionDomain275323052026-09-30RelatedPartyTransactionDomain275323052026-07-012026-09-30RelatedPartyTransactionDomain285323052026-06-30RelatedPartyTransactionDomain285323052026-09-30RelatedPartyTransactionDomain285323052026-07-012026-09-30RelatedPartyTransactionDomain295323052026-06-30RelatedPartyTransactionDomain295323052026-09-30RelatedPartyTransactionDomain295323052026-07-012026-09-30RelatedPartyTransactionDomain305323052026-06-30RelatedPartyTransactionDomain305323052026-09-30RelatedPartyTransactionDomain305323052026-07-012026-09-30RelatedPartyTransactionDomain315323052026-06-30RelatedPartyTransactionDomain315323052026-09-30RelatedPartyTransactionDomain315323052026-07-012026-09-30RelatedPartyTransactionDomain325323052026-06-30RelatedPartyTransactionDomain325323052026-09-30RelatedPartyTransactionDomain325323052026-07-012026-09-30RelatedPartyTransactionDomain335323052026-06-30RelatedPartyTransactionDomain335323052026-09-30RelatedPartyTransactionDomain335323052026-07-012026-09-30AuditorDomain15323052026-09-30Statement15323052026-07-012026-09-30Statement15323052026-09-30Statement25323052026-07-012026-09-30Statement25323052026-09-30StatementDynamic1I1Statement15323052026-09-30StatementDynamic1I2Statement15323052026-09-30StatementDynamic1I3Statement15323052026-09-30StatementDynamic1I4Statement15323052026-09-30StatementDynamic2I1Statement25323052026-09-30StatementDynamic2I2Statement25323052026-09-30StatementDynamic2I3Statement25323052026-09-30StatementDynamic2I4Statement25323052026-09-30StatementDynamic2I5Statement25323052026-09-30StatementDynamic2I6Statement2iso4217:INRxbrli:pureiso4217:INRxbrli:shares532305INDSWFTLABNOTLISTEDINE915B01019IND-SWIFT LABORATORIES LIMITEDMain BoardEquity2026-04-012027-03-312026-10-292026-10-15INRLakhsQuarterlySecond quarterSingle segmentPHARMACEUTICALS2026-10-2912:00:002026-10-2914:45:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNAYesfalsetrue2025-02-13https://www.indswiftlabs.com/wp-content/uploads/2025/05/Related_Party_Policy_01022025.pdftrue2falseNA2026-07-012026-09-30UnauditedStandalone2348904000759870002424891000928619000160540000-2872600037362100013331000777090004915760002016670000408221000-579700040242400092141000092141000031028300000003102830000310283000869616000103.573.56003.573.56Notes: - <br /> 1. During the quarter ended 30th September, 2026, the company has achieved an EBITDA of Rs. 42.33 Crores and earned a Standalone Net Profit of Rs. 31.03 Crores as compared to the EBITDA of Rs. 8.55 Crores and Standalone Net Profit of Rs. 8.76 Crores during the corresponding quarter of previous financial year. <br /> <br /> 2. The above Un-Audited Standalone and Consolidated Financial Results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 29th October, 2026. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. <br /> <br /> 3. The Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30.09.2026 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. <br /> <br /> 4. The figures for the quarter ended March 31, 2026 were the balancing figures between audited figures in respect of full financial year and the year-to-date figures upto the third quarter of the previous financial year. <br /> <br /> 5. Exceptional items for the quarter ended 30th September, 2026 is Rs. 57.97 Lakhs whereas for 30th June, 2026 comprise of Rs. 23.58 Lakhs and for the financial year ended 31st March, 2026 of Rs. 1100.64 Lakhs, towards balances written back/written off (net) on account of amounts no longer payable/receivable. <br /> <br /> 6. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company. <br /> <br /> 7. The Consolidated financial results include the financial results of the parent company, Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture: <br /> a) Ind-Swift Laboratories Inc., USA (Subsidiary) <br /> b) Fortune (India) Constructions Limited (Subsidiary) <br /> c) Indis Healthcare LLP (Joint Venture) <br /> d) MJM Remedies Private Limited (Subsidiary) <br /> e) ISLL Middle East LLC-FZ (Subsidiary) <br /> f) Ind Swift India Limited Kenya (Subsidiary) <br /> g) Capital Strikers LLP (Joint Venture) <br /> Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as ‘the Group’. <br /> <br /> 8. No adjustment has been made in respect of Deferred Taxes as per Ind-AS 12, as the same would be provided at year end. <br /> <br /> 9. During the quarter under review the Company has not issued any Non-Convertible Debt Securities. <br /> <br /> 10. The previous period figures have been re-grouped and re-classified wherever necessary. <br /> <br /> 11. The Company is exclusively in the Pharmaceutical Business segment. <br /> <br /> <br /> <br /> <br /> <br /> Place: Chandigarh For Ind-Swift Laboratories Limited <br /> <br /> <br /> <br /> <br /> Date: 29th October, 2026 Navrattan Munjal <br /> Chairman <br /> <br /> <br /> 2026-04-012026-09-30UnauditedStandalone420972800015226900043619970001745883000293219000-226549000763155000203830001535390008775090003627139000734858000-81550007267030001719780000171978000055472500000005547250000554725000869616000106.386.36006.386.36Other expenses491576000Other expenses8775090002735396000397864000220170000348948000203430000032391970007354400002166900039963060005033700003355770008359821000168351700045028400023478520003228143000003369890006363268000113624500091830300001754285100086961600013736249000146058650001460586500015144500057656000209101000135619000195100034667100043544000808900013288850001336974000159670001396485000110405600027796000619780002590315000293698600017542851000Other21669000Other non-current assets335577000Other current financial assets336989000Other current assets1136245000Other non-current financial liabilities57656000Other non-current liabilities1951000Other current financial liabilities15967000Other current liabilities11040560000-253757000-5236660000-306850000358800000000000153539000000005481900000000-144530000680400051180000-972643000-2459400000001088920000-3548320000000000006700720000383742000000000000000000014543300000-908381000000343000000000017743000000108310000-8548000341364000-9218490000-92184900041499120003228063000000000IND-SWIFT LABORATORIES LIMITED******ESSIX BIOSCIENCES LIMITED******PromoterInvestment15000000000As approved by Board/Shareholders0288506000288506000IND-SWIFT LABORATORIES LIMITED******ESSIX BIOSCIENCES LIMITED******PromoterPurchase of goods or services1500000000As approved by Board/Shareholders170783000329973000142965000IND-SWIFT LABORATORIES LIMITED******MOHALI GREEN ENVIRONMENT PRIVATE LIMITED******Other RPAdvance50000000As approved by Board/Shareholders022000002200000IND-SWIFT LABORATORIES LIMITED******MOHALI GREEN ENVIRONMENT PRIVATE LIMITED******Other RPInvestment15000000000As approved by Board/Shareholders0300000300000IND-SWIFT LABORATORIES LIMITED******IND-SWIFT LABORATORIES INC, USA******Wholly Owned SubsidiarySale of goods or servicesBeing a wholly owned subsidiary, there is no requirement77127000960300036945000IND-SWIFT LABORATORIES LIMITED******IND-SWIFT LABORATORIES INC, USA******Wholly Owned SubsidiaryInvestmentBeing a wholly owned subsidiary, there is no requirement05441000054410000IND-SWIFT LABORATORIES LIMITED******FORTUNE (INDIA) CONSTRUCTIONS LIMITED******Wholly Owned SubsidiaryInvestmentBeing a wholly owned subsidiary, there is no requirement0724840000724840000IND-SWIFT LABORATORIES LIMITED******NAVRATTAN MUNJAL******PromoterRemunerationAs approved by NRC/Board2212800072910007278000IND-SWIFT LABORATORIES LIMITED******HIMANSHU JAIN******PromoterRemunerationAs approved by NRC/Board1621900051390005167000IND-SWIFT LABORATORIES LIMITED******RISHAV MEHTA******PromoterRemunerationAs approved by NRC/Board1770100034950003582000IND-SWIFT LABORATORIES LIMITED******SAHIL MUNJAL******PromoterRemunerationAs approved by NRC/Board1770100056560005361000IND-SWIFT LABORATORIES LIMITED******GAGAN AGGARWAL******CFORemunerationAs approved by NRC/Board334800000IND-SWIFT LABORATORIES LIMITED******PARDEEP VERMA******Company SecretaryRemunerationAs approved by NRC/Board256400000IND-SWIFT LABORATORIES LIMITED******PARDEEP VERMA******Company SecretaryAny other transactionLoans & AdvancesAs approved by NRC/Board0321000321000IND-SWIFT LABORATORIES LIMITED******INDIS HEALTHCARE LLP******Joint VentureInvestment100000000Within the maximum limit as approved by the Board02500000025000000IND-SWIFT LABORATORIES LIMITED******INDIS HEALTHCARE LLP******Joint VentureSale of goods or services500000000Within the maximum limit as approved by the Board1018600089370009290000IND-SWIFT LABORATORIES LIMITED******MJM REMEDIES PRIVATE LIMITED******SubsidiaryInvestment5000000Within the maximum limit as approved by the Board023250002325000IND-SWIFT LABORATORIES LIMITED******ESSIX BIOSCIENCES LIMITED******PromoterSale of goods or services1500000000As approved by Board/Shareholders13000770006000IND-SWIFT LABORATORIES LIMITED******MJM REMEDIES PRIVATE LIMITED******SubsidiarySale of goods or services500000000as approved by audit committee0816000816000IND-SWIFT LABORATORIES LIMITED******ELAN VITAL DRUG STORE LLC******Other RPSale of goods or services500000000as approved by audit committee5135500096707000129859000IND-SWIFT LABORATORIES LIMITED******CHDMM TIBBI OMEHTA******Other RPSale of goods or services500000000as approved by audit committee26940003313200030438000IND-SWIFT LABORATORIES LIMITED******GOPAL MUNJAL******PromoterAny other transactionAdvance against salaryas per HR's policy03457900034579000IND-SWIFT LABORATORIES LIMITED******S.R. MEHTA******PromoterAny other transactionAdvance against salaryas per HR's policy03631900036319000IND-SWIFT LABORATORIES LIMITED******V.R. MEHTA******PromoterAny other transactionAdvance against salaryas per HR's policy03561800035618000IND-SWIFT LABORATORIES LIMITED******MUNJAL JAIN ESTATES PVT LTD******Other RPLoan100000000100026600004661800044778000IND-SWIFT LABORATORIES LIMITED******ISLL MIDDLE EAST L.L.C -FZ******Wholly Owned SubsidiaryInvestmentBeing a wholly owned subsidiary, there is no requirement48475000274617000323092000FORTUNE (INDIA) CONSTRUCTIONS LIMITED******ESSIX BIOSCIENCES LIMITED******Other RPInvestmentas approved by audit committee0155693000155693000The outstanding balance pertains to the period prior to Fortune (India) Constructions Limited becoming a subsidiary of the Company. Fortune (India) Constructions Limited became a subsidiary during FY 2021-22; accordingly, the balance relates to transactions existing before the acquisition.FORTUNE (INDIA) CONSTRUCTIONS LIMITED******ESSIX BIOSCIENCES LIMITED******Other RPInvestmentas approved by audit committee03805500038055000The outstanding balance pertains to the period prior to Fortune (India) Constructions Limited becoming a subsidiary of the Company. Fortune (India) Constructions Limited became a subsidiary during FY 2021-22; accordingly, the balance relates to transactions existing before the acquisition.IND-SWIFT LABORATORIES LIMITED******Gopal Munjal******PromoterRemuneration240000000As approved by Shareholders899400000IND-SWIFT LABORATORIES LIMITED******S.R. Mehta******PromoterRemuneration240000000As approved by Shareholders899400000IND-SWIFT LABORATORIES LIMITED******V.R. Mehta******PromoterRemuneration240000000As approved by Shareholders899400000IND-SWIFT LABORATORIES LIMITED******Capital Strikers LLP******Joint venturesInvestment20000000as approved by Board/Audit Committee02500025000IND-SWIFT LABORATORIES LIMITED******MJM REMEDIES PRIVATE LIMITED******SubsidiaryAdvance500000000as approved by Board/Audit Committee6750000675000470611000UnauditedtrueRATTAN KAUR AND ASSOCIATEStrue2027-01-31Preferential Issues2024-08-3025561250002026-09-30trueCARE RATINGS LIMITEDfalsePARDEEP VERMACompany Secretary and Compliance OfficerChandigarh2026-10-29Preferential Issues2026-09-173430000002026-09-30trueCARE RATINGS LIMITEDfalseExpansion of Business of the Company or the Wholly Owned SubsidiariesNIL1500000000011354160000 Investment in existing or to be acquired SubsidiariesNIL50000000002747070000Working Capital for existing businessNIL39600000003960000000General Corporate PurposeNIL75000000003960000000Expansion of Existing Manufacturing Facility and Setting up of a new WarehouseNIL4140000000631480000Research & Development (‘R&D’)NIL20000000033470000Technology UpgradationNIL15000000000Investment in subsidiaryNIL500000000485300000To meet the Working Capital Requirements of the CompanyNIL5300000000398960000General Corporate PurposeNIL343000000010800000